Connect Biopharma Holdings Limited (CNTB): Price and Financial Metrics
CNTB Price/Volume Stats
| Current price | $0.65 | 52-week high | $1.58 |
| Prev. close | $0.71 | 52-week low | $0.53 |
| Day low | $0.53 | Volume | 105,900 |
| Day high | $0.69 | Avg. volume | 253,301 |
| 50-day MA | $0.90 | Dividend yield | N/A |
| 200-day MA | $1.02 | Market Cap | 35.89M |
CNTB Stock Price Chart Interactive Chart >
Connect Biopharma Holdings Limited (CNTB) Company Bio
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Latest CNTB News From Around the Web
Below are the latest news stories about CONNECT BIOPHARMA HOLDINGS LTD that investors may wish to consider to help them evaluate CNTB as an investment opportunity.
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock?Connect Biopharma Holdings Limited Sponsored ADR (CNTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business UpdateKey data readouts with Company’s lead drug candidate rademikibart expected in the fourth quarter of 2023 Topline results from Stage 2 of the China pivotal trial in atopic dermatitisTopline results from Global Phase 2 trial in asthma Cash balance of $131.6 million expected to support planned operations into at least 2026 SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage |
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementSAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that on September 11, 2023, it received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC ( |
Connect Biopharma to Participate in Upcoming September Investor ConferencesSAN DIEGO and TAICANG, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Connect Biopharma’s management team will participate at the following upcoming investor conferences: H.C. Wainwright 25th |
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of DermatologyFour poster presentations provided detailed and new data on the achievement of primary and secondary endpoints, improvements in investigator-rated outcomes, and improvements in patient reported outcomes from the initial 16-week treatment period with rademikibart (formerly known as CBP-201) in patients with moderate-to-severe atopic dermatitis (AD) in the pivotal CN002 trial in China SAN DIEGO and TAICANG, China, July 10, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) |
CNTB Price Returns
| 1-mo | -20.73% |
| 3-mo | -46.72% |
| 6-mo | -32.29% |
| 1-year | -48.41% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -25.10% |
| 2022 | -83.15% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...